Modern psychiatry is in the fortunate position of having access to a wide range of medications, with differing efficacy and sideeffect profiles, available for the treatment of psychotic disorders.
Among these are the phenothiazines, butyrophenone and thioxanthene derivates, also known as the typical antipsychotics, and the newer so-called second-generation or atypical antipsychotics.
Although antipsychotics offer hope of a normal life to many patients with psychotic illnesses, their usefulness has been limited by their side-effect profile. Antipsychotics are best known for their neurological, particularly extrapyramidal, side-effects but may also have a range of other, non-neurological sideeffects. Among these is an association between the use of antipsychotic medications and ventricular arrhythmias and even sudden death. 1 The implicated drugs prolong ventricular repolarisation, reflected by T-wave changes and prolongation of the QT interval on the electrocardiogram (ECG).
The QT interval is an ECG measure that includes both ventricular depolarisation and repolarisation. It begins with the onset of ventricular depolarisation (Q-wave) and ends with the completion of repolarisation (T-wave). Because the QT interval shortens with increasing heart rates, this is usually corrected for.
The formula most commonly used to obtain the corrected QT interval (QTc) is Bazett's formula: QTc = √RR where the QTo is the observed QT interval. QTc intervals below 440 milliseconds are considered normal. The greater the duration of QTc, the more likely cardiac arrhythmias become, with 500 milliseconds considered the threshold for safety. QTc intervals longer than this are associated with substantially higher risk of arrhythmias. Objective. The purpose of this study was to determine whether these warnings are of clinical relevance in a setting where there are already a limited number of antipsychotics available.
Method. Thirty hospitalised subjects who required switching from a high-potency to a low-potency antipsychotic were included. All subjects were commenced on thioridazine 300 mg per day and had an ECG 1 week after initiation and 48 hours after each dose adjustment. QTc was determined using Bazett's formula. Despite the cardiovascular risk that it may present, thioridazine has long been used as a first-line antipsychotic in many institutions in this country, with little apparent adverse effect.
More recently, however, many South African health institutions have followed the advice of the Food and Drug Administration (FDA) in the USA, namely that thioridazine should no longer be used as a first-line antipsychotic medication. Although we have applied the same restrictions at our hospital, we were interested to know whether this issue was clinically relevant in our population, as this would further limit the number of antipsychotic medications available and also restrict the use of a seemingly well-tolerated alternative to the high-potency antipsychotics. The purpose of this study was therefore to establish whether thioridazine causes clinically significant QTc interval changes, at the dosages used at our institution.
Methods
This was an open-label study, with subjects serving as their own controls. All subjects were inpatients at Stikland Hospital in Cape Town aged between 18 and 60 years (inclusive) at the time of the study. Subjects were considered for inclusion if they had a Diagnostic and Statistical Manual (DSM-IV) diagnosis of a psychotic disorder for which they required a change of therapy from another antipsychotic (usually haloperidol) to a low-potency medication such as thioridazine. This change of therapy could have been due to side-effects, non-response, or patient request. Subjects were excluded if they had any comorbid cardiovascular disease (ischaemic heart disease, arrhythmias) or were on treatment with propranolol, pindolol or any medication known to inhibit the cytochrome P450 system.
Concomitant treatment with any medication known to increase the QT interval was also not allowed. Other exclusion criteria were subjects with immediate suicide risk, known hypersensitivity to thioridazine, electroconvulsive therapy in the past 3 months and medical conditions in which thioridazine is contraindicated, e.g. hepatic dysfunction and glaucoma. The study protocol, patient information and consent procedures were approved by the Institutional Review Board of Stellenbosch University.
After receiving information on the purpose and method of the study, all subjects provided written, informed consent before any study procedures were undertaken. Demographic details, vital signs, medical, surgical and treatment history as well as ECG were obtained at baseline. Thereafter, the first-line medication was discontinued and thioridazine commenced at a dosage of 300 mg/day. Dosages were increased on a weekly basis in increments of 100 mg/day until the desired antipsychotic effect was achieved, intolerable side-effects developed or a total daily dosage of 800 mg/day was reached. Downward titration was allowed at any time. The maximum allowed daily dosage of thioridazine was 800 mg/day. Thioridazine was discontinued immediately in any subject found to have a QTc interval equal to or greater than 500 milliseconds.
Follow-up ECGs were obtained 1 week after initiation of thioridazine, and 48 hours after any dosage adjustment.
Measurement of the QT interval was performed manually by counting the small marked squares on the ECG paper, each square representing 0.04 seconds. All measurements were done by a single rater (CS).
Statistical methods
Statistical analysis was performed with the help of a specialised computer software package, Statistica version 6 (Statsoft, Inc. 
Results
A total of 36 subjects were evaluated for inclusion during the recruitment period. Six subjects failed to meet inclusion criteria and therefore the final sample consisted of a total of 30 subjects, of whom 17 (57%) were male. The mean age for the whole sample was 35.3 (± 11.6) years, and 31.8 (± 10.9) years and 38.9 (± 11.8) years for males and females, respectively. Twenty-five subjects had a diagnosis of schizophrenia, 3
had a diagnosis of schizophreniform disorder and 2 were subjects.
In the second study, Hartigan-Go et al. 19 did a randomised, double-blind, three-period crossover study involving 9 healthy male subjects. They reported a dose-related prolongation of the to abnormal levels in almost one-quarter of subjects and to dangerous levels in 2 patients. Furthermore, these changes were asymptomatic and would not have been picked up had ECG monitoring not been done. As in other studies, we found that the increase was greater in females than in males, although the difference did not reach statistical significance. However, both subjects whose medication had to be discontinued were female. In contrast to what is suggested in the 'black box' warning, we did not find any association between dose and QTc prolongation; however a longer baseline QTc did seem to increase the risk.
Although pimozide, sulpiride and droperidol may also prolong the QTc interval and have also been associated with torsades de pointes and sudden death, they were never used as widely as thioridazine. Even haloperidol can induce torsades de pointes and may cause sudden death at normal therapeutic doses, but it does so substantially less frequently than thioridazine. 21 It should also be noted that, despite their generally enhanced safety and tolerability, some atypical antipsychotics have also been associated with QTc interval prolongation. 22 Sertindole has been associated with serious but non-fatal arrhythmias but also with cases of sudden death. 23 Although olanzapine, quetiapine and risperidone prolong the QT interval, it is not clear that they cause torsades de pointes or ventricular fibrillation. 22 At this time, the most compelling evidence for antipsychotic drug-induced cardiac arrhythmias and sudden death exist with thioridazine. 24 It has been associated with numerous cases of torsades de pointes and sudden death. 25 When QT-interval prolongation of antipsychotics have been compared, they were found to be -in decreasing order of magnitudethioridazine, sertindole, ziprasidone, quetiapine, risperidone, olanzapine, and haloperidol. 22 However, it is important to remember that despite being the best predictor variable of Despite the limitations, this study confirms that significant QTinterval prolongation may be a problem at normal therapeutic doses of thioridazine in our population. Until we have better predictors available for assessing cardiovascular safety, we suggest pretreatment and follow-up ECG, and adherence to FDA stipulations as set out above.
Additional suggestions as prescribed in previous studies are: 24, 25 (i) medical history concentrating on previous episodes of syncope, previous heart disease, relatives with long-QT articles syndrome, and family history of sudden death; and (ii) enquiring about the use of other medications that may also prolong the QT interval.
